Ubs Group Ag Elevation Oncology, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 42,590 shares of ELEV stock, worth $27,683. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,590

Previous 15,829 169.06%

Holding current value

$27,683

Previous $42,000 40.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.56 - $3.02 $14,986 - $80,818	26,761 Added 169.06%	42,590 $25,000
Q2 2024 Aug 13, 2024	SELL	$2.35 - $5.17 $250,829 - $551,825	-106,736 Reduced 87.09%	15,829 $42,000
Q1 2024 May 13, 2024	SELL	$0.59 - $5.13 $3,481 - $30,267	-5,900 Reduced 4.59%	122,565 $628,000
Q4 2023 Feb 09, 2024	BUY	$0.38 - $0.69 $1,483 - $2,693	3,904 Added 3.13%	128,465 $69,000
Q3 2023 Nov 09, 2023	BUY	$0.65 - $1.56 $70,513 - $169,233	108,483 Added 674.73%	124,561 $82,000
Q2 2023 Aug 11, 2023	BUY	$1.4 - $5.06 $22,369 - $80,848	15,978 Added 15978.0%	16,078 $24,000
Q1 2023 May 12, 2023	SELL	$0.75 - $2.55 $1,261 - $4,289	-1,682 Reduced 94.39%	100 $0
Q4 2022 Feb 08, 2023	BUY	$0.89 - $1.19 $1,585 - $2,120	1,782 New	1,782 $1,000
Q1 2022 May 16, 2022	SELL	$2.34 - $6.41 $5,662 - $15,512	-2,420 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.15 - $8.86 $10,043 - $21,441	2,420 New	2,420 $15,000
Q3 2021 Nov 15, 2021	SELL	$7.66 - $16.11 $8,004 - $16,834	-1,045 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$11.44 - $13.57 $11,954 - $14,180	1,045 New	1,045 $14,000

Others Institutions Holding ELEV

# of Institutions

Shares Held

45.4M

Call Options Held

700

Put Options Held

27.6K

View Full List

About Elevation Oncology, Inc.

Ticker ELEV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,300,900
Market Cap $15.1M
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...

More about ELEV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account